Evidence map›Paper›PMID 37347514›Full record

ArticleJMIR formative research2023

Identifying Patient Populations in Texts Describing Drug Approvals Through Deep Learning-Based Information Extraction: Development of a Natural Language Processing Algorithm.

Aline Gendrin, Leonidas Souliotis, James Loudon-Griffiths, Ravisha Aggarwal, Daniel Amoako, Gregory Desouza, Sashka Dimitrievska, Paul Metcalfe, Emilie Louvet, Harpreet Sahni

Abstract read
In one paragraph

Article in JMIR formative research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aline GendrinAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0001-6722-9369
Leonidas SouliotisAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0009-0001-4540-7344
James Loudon-GriffithsAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0009-0002-1501-2031
Ravisha AggarwalAstraZeneca, Bangalore, India.ORCID https://orcid.org/0009-0002-6701-6691
Daniel AmoakoAstraZeneca, Wilmington, DE, United States.ORCID https://orcid.org/0009-0005-4062-9174
Gregory DesouzaAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0009-0009-0372-3136
Sashka DimitrievskaAstraZeneca, Gaithersburg, MD, United States.ORCID https://orcid.org/0009-0002-0296-9344
Paul MetcalfeAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0009-0001-0644-4724
Emilie LouvetAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0009-0006-1396-4265
Harpreet SahniAstraZeneca, Wilmington, DE, United States.ORCID https://orcid.org/0009-0008-8305-5889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew drug treatments are regularly approved, and it is challenging to remain up-to-date in this rapidly changing environment. Fast and accurate visualization is important to allow a global understanding of the drug market. Automation of this information extraction provides a helpful starting point for the subject matter expert, helps to mitigate human errors, and saves time.

objectiveWe aimed to semiautomate disease population extraction from the free text of oncology drug approval descriptions from the BioMedTracker database for 6 selected drug targets. More specifically, we intended to extract (1) line of therapy, (2) stage of cancer of the patient population described in the approval, and (3) the clinical trials that provide evidence for the approval. We aimed to use these results in downstream applications, aiding the searchability of relevant content against related drug project sources.

methodsWe fine-tuned a state-of-the-art deep learning model, Bidirectional Encoder Representations from Transformers, for each of the 3 desired outputs. We independently applied rule-based text mining approaches. We compared the performances of deep learning and rule-based approaches and selected the best method, which was then applied to new entries. The results were manually curated by a subject matter expert and then used to train new models.

resultsThe training data set is currently small (433 entries) and will enlarge over time when new approval descriptions become available or if a choice is made to take another drug target into account. The deep learning models achieved 61% and 56% 5-fold cross-validated accuracies for line of therapy and stage of cancer, respectively, which were treated as classification tasks. Trial identification is treated as a named entity recognition task, and the 5-fold cross-validated F

conclusionsWe developed a natural language processing algorithm that is currently assisting subject matter experts in disease population extraction, which supports health authority approvals. This algorithm achieves semiautomation, enabling subject matter experts to leverage the results for deeper analysis and to accelerate information retrieval in a crowded clinical environment such as oncology.

Indexed as

algorithmartificial intelligenceBERTcancerclassificationdata extractiondata miningdeep-learningdevelopmentdrug approvalfree textinformation retrievalline of therapymachine learningnatural language processingNLPoncologypharmaceuticpharmacologypharmacystage of cancertext extractiontext miningunstructured data

Identifiers

PMID37347514
PMCPMC10337300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.